Abstracts tagged "Antibodies"

Abstract Number: 2008 • 2014 ACR/ARHP Annual Meeting
Personalized Risk Education for Rheumatoid Arthritis Improves Self-Perceived Risk Accuracy and Risk Factor Knowledge in First-Degree Relatives
Jeffrey A. Sparks¹, Maura D. Iversen^1,2,3, Rachel Miller Kroouze^1,4, Nellie A. Triedman¹, Taysir G. Mahmoud¹, Sarah S. Kalia⁴, Michael L. Atkinson⁵, Robert C. Green⁴ and Elizabeth W. Karlson¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Department of Physical Therapy, Movement & Rehabilitation Sciences, Northeastern University, Boston, MA, ³Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Having a first-degree relative (FDR) with RA increases personal RA risk by four-fold. Other RA risk factors include demographics, genetics, auto-antibodies, and behaviors. We…
Abstract Number: 1703 • 2014 ACR/ARHP Annual Meeting
An Association of Anti-PM/Scl Antibody Reactivity with Risk of Malignancy in Scleroderma
Cosimo Bruni¹, Ana Lages², Hitesh Patel³, Jennifer Harvey³, Voon H. Ong⁴, Marco Matucci-Cerinic¹, Emma C. Derrett-Smith⁵ and Christopher P Denton⁶, ¹Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ²Affiliation servicio de Medicina Interna, Hospital De Braga, Braga, Portugal, ³Department of Clinical Immunology, Royal Free Hospital, London, United Kingdom, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School Royal Free Campus, London, United Kingdom, ⁶Centre for Rheumatology and Connective Tissue Disease, UCL Medical School Royal Free Campus, London, United Kingdom
Association of anti-PM/Scl antibody with risk of malignancy in scleroderma. C. Bruni¹, A. Lages², H. Patel3, J. Harvey3, V. Ong4, M. Matucci-Cerinic¹, E. Derrett-Smith4, C.P.…
Abstract Number: 1620 • 2014 ACR/ARHP Annual Meeting
Antibody to Malondialdehyde-Acetaldehyde Adducts (MAA) As a Potential Biomarker of Inflammation in Systemic Lupus Erythrematosus (SLE)
Andy Hollins¹, Michael Duryee², Michelene Hearth-Holmes³, Ted R. Mikuls¹, Zhixin Zhang⁴, Kaihong Su⁵ and Geoffrey M. Thiele⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine/Rheumatology Division, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁵Eppley Cancer Institute, University of Nebraska Medical Center, Omaha, NE, ⁶Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose Studies have shown that malondialdehyde-acetaldehyde (MAA) is formed as a result of lipid peroxidation of cellular membranes and is capable of binding or adducting…
Abstract Number: 1309 • 2014 ACR/ARHP Annual Meeting
Does Anti-C1q Antibody Have Diagnostic and Prognostic Roles in Childhood – Onset Systemic Lupus Erythematosus?
Thaschawee Arkachaisri¹, Joo Guan Yeo², Justin Hung Tiong Tan³, Sook Fun Hoh⁴, Lena Das³ and Jing Yao Leong², ¹Rheumatology & Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Children Intensive Care Unit (CICU), KK Women's and Children's Hospital, Singapore, Singapore, ³Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ⁴Nursing, KK Women's and Children's Hospital, Singapore, Singapore
Background/Purpose: Biomarkers proven to be effective in aSLE patients may not directly apply to cSLE unless validation is done. Existing evidences have shown immunopathogenic roles…
Abstract Number: 1251 • 2013 ACR/ARHP Annual Meeting
Collagen Antibodies Induce Pain-Like Behavior In Mice Without Signs Of Inflammation
Gustaf Wigerblad¹, Katalin Sandor¹, Kutty Selva Nandakumar², Rikard Holmdahl³ and Camilla Svensson¹, ¹Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, ²Department of Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, ³Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Collagen Antibody Induced Arthritis (CAIA) is a mouse model of rheumatoid arthritis (RA). It is induced by injection of a cocktail of monoclonal antibodies…
Abstract Number: 920 • 2013 ACR/ARHP Annual Meeting
Fms-Like Tyrosine Kinase 3 Signaling Is Essential For Differentiation Of Antigen Specific Plasma Cells During Experimental Arthritis
Mattias Svensson¹, Kersti Månsson¹, Karin Andersson¹, Mats Bemark², Mikael Brisslert¹ and Maria Bokarewa¹, ¹Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ²Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Signaling through the tyrosine kinase receptor Flt3 plays an important role in early B-cell development. Mice lacking either Flt3 or its ligand (Flt3L) have…
Abstract Number: 714 • 2013 ACR/ARHP Annual Meeting
Combination Blocking Of Interleukin-6 and Interleukin-21 In Experimental Arthritis Inhibits Their Redundant Role In T Helper 17-Driven Joint Pathology
Debbie M. Roeleveld¹, Marije I. Koenders², Renoud J. Marijnissen^1,3, Cheryl L. Nickerson-Nutter⁴, Fons A. van de Loo¹ and Wim B. van den Berg⁵, ¹Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, Netherlands, ⁴Immunology and Autoimmunity, Pfizer, Cambridge, MA, ⁵Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Both IL-6 and IL-21 have been described to drive in vitro Th17 differentiation in the presence of TGF-β. We explored whether also in vivo…
Abstract Number: 674 • 2013 ACR/ARHP Annual Meeting
Systemic Sclerosis Disease Subset Is a Better Predictor Of Long Term Outcome Than Autoantibody Profile
Svetlana I. Nihtyanova¹, Voon H. Ong² and Christopher P. Denton³, ¹Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ²Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, ³Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom
Background/Purpose: Disease subset has been shown to strongly correlate with survival and risk of organ complications in patients with systemic sclerosis (SSc). Nevertheless evidence in…
Abstract Number: 38 • 2013 ACR/ARHP Annual Meeting
Use Of An In Vitro Whole Blood Depletion ASSAY To Compare The Efficacy Of B CELL Depleting Agents In Patients With Systemic LUPUS Erythematosus
Venkat Reddy¹, Geraldine Cambridge², D.A. Isenberg³, Mark Cragg⁴ and Maria Leandro⁵, ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom, ⁵Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Variability in clinical response to B-cell depletion therapy (BCDT) with the anti-CD20mAb rituximab (RTX) has been well described in Systemic Lupus Erythematosus (SLE). Poor…
Abstract Number: 7 • 2013 ACR/ARHP Annual Meeting
Prospective Validation Of The Global Antiphospholipid Syndrome Score (GAPSS)
Savino Sciascia¹, Mª Jose Cuadrado², Giovanni Sanna³, Veronica Murru⁴, Dario Roccatello¹, Oier Ateka⁵, Munther A. Khamashta⁶ and Maria Laura Bertolaccini⁴, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Lupus Research Unit, The Rayne Institute, London, United Kingdom, ³Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, ⁴Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ⁵Lupus Unit, London, United Kingdom, ⁶Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Prospective Validation of the Global Antiphospholipid Syndrome Score (GAPSS) Background/Purpose: Backgrounds: This study was performed to prospectively and independently validate the GAPSS (1) (Global APS…
Abstract Number: 2916 • 2013 ACR/ARHP Annual Meeting
Anti-Fibrillarin Antibodies Are Associated With More Severe Gastrointestinal Involvement and Poorer Survival
Shervin Assassi¹, Marie Hudson², Maureen D. Mayes³, Jennifer Walker⁴, Murray Baron^5,6, Wendy Stevens⁷, Karen Patterson⁸, Tiffany Graham¹, Solene Tatibouet⁹, James Wick¹⁰, Matt Stephenson¹¹ and Marvin J. Fritzler¹¹, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³University of Texas Health Science Center at Houston, Houston, TX, ⁴Flinders Medical Centre, Adelaide, Australia, ⁵McGill University, Montreal, QC, Canada, ⁶MCGill University, Montreal, QC, Canada, ⁷Rheumatology, St Vincent's Hospital, Melbourne, Australia, ⁸Institute of Medical and Veterinary Science, North Adelaide, Australia, ⁹Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹⁰Department of medicine, Faculty of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Anti-fibrillarin (U3-RNP) antibodies (AFA) are a relatively specific biomarker for systemic sclerosis (SSc). Previous studies have indicated a higher prevalence of AFA among African…
Abstract Number: 2593 • 2013 ACR/ARHP Annual Meeting
The Prognosis Of Scleroderma Renal Crisis In RNA-Polymerase III Antibody (ARA) Positive Compared To ARA Negative Patients
Bernadette Lynch¹, Henry Penn², Jennifer Harvey³, Aine Burns⁴ and Christopher P. Denton⁵, ¹Department of Rheumatology, The Royal Free Hospital, London, United Kingdom, ²Northwick Park Hospital, Harrow, United Kingdom, ³Clinical Immunology, Royal Free Hospital, London, United Kingdom, ⁴Department of Nephrology, The Royal Free Hospital, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom
Background/Purpose: Scleroderma renal crisis (SRC) usually presenting with accelerated hypertension and acute kidney injury (AKI) is one of the most severe complications of Systemic Sclerosis…
Abstract Number: 2588 • 2013 ACR/ARHP Annual Meeting
Pulmonary Hypertension In Patients With Anti-U1-RNP Antibodies
Vincent Sobanski¹, Bernadette Lynch², Benjamin E. Schreiber³, Svetlana I. Nihtyanova⁴, Jennifer Harvey⁵, Clive Handler⁶, Christopher P. Denton⁷ and John G. Coghlan⁸, ¹Department of Rheumatology, Royal Free Hospital, London, United Kingdom, ²Department of Rheumatology, The Royal Free Hospital, London, United Kingdom, ³Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, ⁴Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ⁵Clinical Immunology, Royal Free Hospital, London, United Kingdom, ⁶Department of Pulmonary Hypertension, The Royal Free Hospital, London, United Kingdom, ⁷Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ⁸National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of morbidity and mortality in patients with connective tissue diseases (CTD). Patients with anti-U1-RNP antibodies belong to…
Abstract Number: 2508 • 2013 ACR/ARHP Annual Meeting
Clinical and Serological Discordance In The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Cohort
Murray B. Urowitz¹, Dafna D. Gladman¹, Nicole Anderson¹ and Systemic Lupus Erythematosus International Collaborating Clinics SLICC², ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Anti-DNA antibodies and serum complement levels are considered important biomarkers for disease activity in SLE. Despite this many SLE patients present serologically active (positive…
Abstract Number: 2030 • 2013 ACR/ARHP Annual Meeting
Comparative Immunogenicity Of Tumor Necrosis Factor Inhibitors: Impact On Clinical Efficacy and Tolerability In The Management Of Autoimmune Diseases: A Systematic Review and Meta-Analysis
Sarah Thomas¹, Nabeel Borazan², Lewei Duan³, Nashla Barroso⁴, Sara Taroumian⁵, Banjamin Kretzmann⁶, Ricardo Bardales⁶ and Daniel Furst¹, ¹Medicine, University of California, Los Angeles, Los Angeles, CA, ²Medicine, Rheumatology UCLA, Los Angeles, CA, ³David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, ⁴Division of Rheumatology, David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, ⁵Department of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ⁶Rheumatology, University of California Los Angeles, los angeles, CA

AbstractBackground/Purpose: Tumor necrosis factor inhibitors (TNFi) are a mainstay in the treatment of rheumatoid arthritis (RA), as well as the management of spondyloarthritis (SpA) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].